Sleep Quality and Levodopa Intestinal Gel Infusion in Parkinson’s Disease: A Pilot Study
Table 3
Comparison of polysomnographic results before and after 6 months of LCIG infusion therapy in 7 patients with advanced PD.
Variables
LCIG infusion therapy
value
Before
At 6 months
Sleep efficiency (%)
66.7 ± 8.4
57.8 ± 16.0
0.173
Wake after sleep onset (WASO) (min)
119.9 ± 74.2
113.0 ± 54.1
0.345
Sleep latency (min)
29.7 ± 40.5
71.2 ± 97.2
0.345
REM latency (min)
147.3 ± 72.4
139.8 ± 63.1
0.893
REM sleep (%)
16.2 ± 9.9
10.4 ± 6.8
0.080
NREM sleep (%)
83.6 ± 10.2
89.6 ± 6.8
0.080
Stage 1
16.8 ± 10.0
23.8 ± 13.7
0.463
Stage 2
52.9 ± 8.4
52.4 ± 12.0
0.345
Stage 3
13.9 ± 7.5
13.0 ± 11.9
0.752
Snoring sounds (number/hour)
323.2 ± 279.3
228.6 ± 226.0
0.715
Apnea-hypopnea index (AHI)
11.8 ± 18.0
12.7 ± 14.0
0.686
Arousal index
15.0 ± 7.0
12.9 ± 5.6
0.115
Spontaneous arousals
7.5 ± 3.1
5.2 ± 5.0
0.075
Respiratory effort-related arousals (RERA)
4.9 ± 7.2
4.8 ± 4.1
0.893
Leg movement arousals
3.1 ± 2.3
2.9 ± 2.5
0.462
Periodic leg movement in sleep (PLMS)
12.5 ± 11.6
7.7 ± 11.1
0.345
PLMS in REM sleep
20.7 ± 31.6
2.9 ± 3.7
0.285
PLMS in NREM sleep
10.3 ± 9.5
8.3 ± 12.4
0.893
Oxygen saturation (SpO2) (%)
Baseline
95.1 ± 2.3
95.8 ± 2.1
0.339
Mean
93.8 ± 2.0
94.3 ± 2.2
0.461
Minimum
87.0 ± 8.9
86.4 ± 6.6
0.672
Oxygen saturation <90%, CT90 (%)
2.7 ± 4.2
1.7 ± 2.0
0.416
Data as mean ± standard deviation. 6–10: higher normal daytime sleepiness. 11–12: mild excessive daytime sleepiness. 13–15: moderate excessive daytime sleepiness. 16–24: severe excessive daytime sleepiness.
